ARS Pharmaceuticals, Inc. (SPRY)
(Real Time Quote from BATS)
$8.91 USD
-0.07 (-0.78%)
Updated May 29, 2024 12:34 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SPRY 8.91 -0.07(-0.78%)
Will SPRY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray
Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down
ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray
Other News for SPRY
Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)
ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...
ARS Pharmaceuticals Unveils Updated Corporate Presentation
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024